Robbins LLP Encourages ZBIO Stockholders to Step Forward for Class Action Initiative

Important Update for Zenas BioPharma Shareholders

On May 27, 2025, Robbins LLP announced a class action lawsuit on behalf of investors who purchased Zenas BioPharma, Inc. (NASDAQ: ZBIO) shares, particularly those acquired during the company's September 2024 initial public offering (IPO). Zenas BioPharma claims to be a pioneering clinical-stage biopharmaceutical firm focused on advancing immunology-based therapies.

Details of the Allegations

The lawsuit centers on allegations that Zenas BioPharma misled investors regarding its financial stability in the prospectus related to its IPO. Specifically, the complaint asserts that the company significantly exaggerated the duration for which it could sustain its operational funding based on its existing cash reserves and anticipated IPO proceeds. Initially, Zenas had communicated that it could operate for 24 months; however, a filing with the SEC dated November 12, 2024, revealed the company could only support itself for 12 months.

This stark discrepancy has had a severe impact on Zenas BioPharma's stock value. Following the release of this crucial information, the stock price plummeted, closing at $8.72—a 48.7% decrease from its original IPO price by April 15, 2025.

Participation in the Class Action

Robbins LLP is urging affected shareholders to act quickly. Those interested in serving as lead plaintiffs for the class action must file their applications with the court by June 16, 2025. This position is integral as lead plaintiffs represent the interests of all participating class members throughout the legal proceedings. It’s noteworthy that individuals do not have to engage in the case to qualify for any potential recovery; simply remaining with the class is sufficient.

Robbins LLP operates on a contingency fee basis, meaning shareholders will incur no costs unless a recovery is granted.

About Robbins LLP

Established in 2002, Robbins LLP is recognized as a leader in shareholder rights litigation. The firm is committed to helping shareholders reclaim their financial losses, enhancing corporate governance practices, and holding executives accountable for any misdeeds. If you wish to receive timely notifications regarding settlement updates for the class action against Zenas BioPharma or alerts about corporate discrepancies, consider registering for the Stock Watch service offered by Robbins LLP.

Next Steps

If you are a shareholder of Zenas BioPharma and wish to know more about your rights or how to take part in the class action suit, please fill out the form available on Robbins LLP’s website. For immediate inquiries, you can also reach attorney Aaron Dumas, Jr., via email or by calling (800) 350-6003.

Stay informed and proactive in protecting your investment—act now to learn how you can be part of this critical class action against Zenas BioPharma, Inc.